Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - salbutamol sulfate -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; macrogol 4000; hypromellose; titanium dioxide; microcrystalline cellulose; powdered cellulose - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis.acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae;combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. clarithromycin sandoz clarithromycin is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro organisms in the conditions listed below:acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; skin and skin structure infections (eg impetigo); disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. acute otitis media.note:1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefazolin sodium, quantity: 2096 mg (equivalent: cefazolin, qty 2000 mg) - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present. genitourinary tract infections due to e. coli, p. mirabilis, and klebsiella sp. and some strains of enterobacter and enterococci. skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resisant) and group a beta-haemolytic streptococci and other strains of streptococci. bone and joint infections due to staph. aureus. septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), e. coli, p. mirabilis, and klebsiella sp. endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. note: appropriate culture and susceptibility studies should be preformed to determine susceptibility of the causative organism to cephazolin.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefazolin sodium, quantity: 1048 mg (equivalent: cefazolin, qty 1000 mg) - injection, powder for - excipient ingredients: - indications: treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin is effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present. genitourinary tract infections due to e. coli, p. mirabilis, and klebsiella sp and some strains of enterobacter and enterococci. skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resisant) and group a beta-haemolytic streptococci and other strains of streptococci. bone and joint infections due to staph. aureus. septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), e. coli, p. mirabilis, and klebsiella sp. endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be preformed to determine susceptibility of the causative organism to cephazolin.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; hypromellose; magnesium stearate; croscarmellose sodium; sucrose; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate sandoz is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes. fenofibrate sandoz is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. fenofibrate sandoz does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pregabalin, quantity: 300 mg - capsule - excipient ingredients: maize starch; iron oxide yellow; iron oxide black; purified talc; iron oxide red; titanium dioxide; gelatin; pregelatinised maize starch - pregabalin sandoz is indicated for the treatment of neuropathic pain in adults. pregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pregabalin, quantity: 25 mg - capsule - excipient ingredients: iron oxide red; iron oxide yellow; titanium dioxide; gelatin; iron oxide black; maize starch; pregelatinised maize starch; purified talc - pregabalin sandoz is indicated for the treatment of neuropathic pain in adults. pregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pregabalin, quantity: 150 mg - capsule - excipient ingredients: maize starch; gelatin; titanium dioxide; pregelatinised maize starch; purified talc - pregabalin sandoz is indicated for the treatment of neuropathic pain in adults. pregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pregabalin, quantity: 75 mg - capsule - excipient ingredients: pregelatinised maize starch; iron oxide red; gelatin; titanium dioxide; purified talc; iron oxide yellow; maize starch - pregabalin sandoz is indicated for the treatment of neuropathic pain in adults. pregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.